Department of Medical Oncology, Cancer Center & Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China; Department of Gastrointestinal Surgery, Chengdu Second People's Hospital, No. 10 Qinyun Nan Street, Chengdu, Sichuan Province, People's Republic of China.
Department of Medical Oncology, Cancer Center & Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870(1):166881. doi: 10.1016/j.bbadis.2023.166881. Epub 2023 Sep 9.
Gastric cancer (GC) is an increasing global health problem and is one of the leading cancers worldwide. Traditional therapies, such as radiation and chemotherapy, have made limited progress in enhancing their efficacy for advanced GC. The development of immunotherapy for advanced GC has considerably improved with a deeper understanding of the tumor microenvironment. Immunotherapy using checkpoint inhibitors is a new therapeutic option that has made substantial advances in the treatment of other malignancies and is increasingly used in other clinical oncology treatments. Particularly, therapeutic antibodies targeting the programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have been effectively used in the clinical treatment of cancer. Monoclonal antibodies blocking the PD-1/PD-L1 pathway have been developed for cancer immunotherapy to enhance T cell function to restore the immune response and represent a breakthrough in the treatment of GC. This review provides an outline of the progress of PD-1/PD-L1 blockade therapy and its expression characteristics and clinical application in advanced GC.
胃癌（GC）是一个日益严重的全球健康问题，也是全球领先的癌症之一。传统疗法，如放疗和化疗，在提高晚期 GC 的疗效方面进展有限。随着对肿瘤微环境的深入了解，晚期 GC 的免疫治疗取得了相当大的进展。免疫检查点抑制剂的免疫治疗是一种新的治疗选择，在治疗其他恶性肿瘤方面取得了重大进展，并越来越多地应用于其他临床肿瘤治疗中。特别是，针对程序性细胞死亡蛋白 1（PD-1）/程序性细胞死亡配体 1（PD-L1）途径的治疗性抗体已在癌症的临床治疗中得到有效应用。为了增强 T 细胞功能以恢复免疫反应，用于癌症免疫治疗的阻断 PD-1/PD-L1 通路的单克隆抗体已经得到开发，这代表着 GC 治疗的一个突破。本文综述了 PD-1/PD-L1 阻断治疗及其在晚期 GC 中的表达特征和临床应用的进展。
Zotero 插件